EP0391796A1 - New imidazole derivatives, process for their production and pharmaceutical compositions containing them - Google Patents

New imidazole derivatives, process for their production and pharmaceutical compositions containing them Download PDF

Info

Publication number
EP0391796A1
EP0391796A1 EP90400918A EP90400918A EP0391796A1 EP 0391796 A1 EP0391796 A1 EP 0391796A1 EP 90400918 A EP90400918 A EP 90400918A EP 90400918 A EP90400918 A EP 90400918A EP 0391796 A1 EP0391796 A1 EP 0391796A1
Authority
EP
European Patent Office
Prior art keywords
methoxy
pyran
tetrahydro
diphenylimidazol
thiomethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90400918A
Other languages
German (de)
French (fr)
Inventor
Edward Charles John Coffee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Sante SA
Original Assignee
Rhone Poulenc Sante SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Sante SA filed Critical Rhone Poulenc Sante SA
Publication of EP0391796A1 publication Critical patent/EP0391796A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Definitions

  • This invention relates to new, therapeutically useful imidazole derivatives, to a process for their production and to pharmaceutical compositions containing them.
  • the new imidazole derivatives of the present invention are the compounds of formulae (I) and (II) hereinafter depicted.
  • the compounds according to the invention are:-
  • the invention also encompasses mixtures of compounds (I) and (II).
  • the compounds according to the invention are inhibitors of acyl coenzyme-A:cholesterol-O-acyl transferase (ACAT;EC 2.3.1.26). They are therefore of value as anti-atherosclerotic agents and have utility in the treatment of atherosclerosis, hyperlipidaemia, cholesterol ester storage disease and atheroma in vein grafts.
  • ACAT acyl coenzyme-A:cholesterol-O-acyl transferase
  • IC50 is the concentration required to produce a 50% inhibition in the activity of acyl coenzyme-A:cholesterol-O-acyl transferase.
  • Table 1 Compound IC50(nM) (I) 50 (II) 91
  • the compounds of formulae (I) and (II) are made by the desilylation of compounds of formula (III), in which R1, R2, and R3 , which can be identical or different, each represent a straight or branched-chain alkyl group containing 1 to 4 carbon atoms, or an optionally substituted phenyl group (the optional substituent being one which is inert to the reaction conditions and which does not cause any reaction other than the desilylation to occur).
  • a conventional reagent such as an ammonium fluoride (e.g. tetrabutylammonium fluoride) in an anhydrous, inert solvent (e.g. an ether, such as tetrahydrofuran), preferably at room temperature.
  • an ammonium fluoride e.g. tetrabutylammonium fluoride
  • an anhydrous, inert solvent e.g. an ether, such as tetrahydrofuran
  • the group SiR1R2R3 can
  • Compounds of formula (III) are made by the reaction of the compounds of formula (IV), wherein R1, R2, and R3 are as hereinabove defined, with the compound of formula (V). This reaction is carried out, preferably under dry conditions, in the presence of a base, such as potassium carbonate, optionally under an inert atmosphere (e.g. argon), in an inert solvent, such as dimethylsulphoxide, optionally with heating (e.g. up to 60°C).
  • a base such as potassium carbonate
  • an inert atmosphere e.g. argon
  • an inert solvent such as dimethylsulphoxide
  • This reaction may result in epimerisation at the methoxy-bearing carbon atom and as a result the desilylation reaction which gives the compounds of formulae (I) and (II) may produce an anomeric mixture.
  • Compounds (I) and (II) can be separated by conventional means, such as chromatography over silica gel using a suitable eluant.
  • the compounds of formula (IV) may be made by the method of T. Rosen et.al. [J.Org.Chem, (1984), 49 , 3994].
  • the present invention also includes within its scope pharmaceutical formulations which comprise the compound(s) of formula(e) (I) and/or (II) in association with a pharmaceutically acceptable carrier or coating.
  • pharmaceutical formulations which comprise the compound(s) of formula(e) (I) and/or (II) in association with a pharmaceutically acceptable carrier or coating.
  • the compounds of the present invention may be administered parenterally, rectally or orally.
  • Solid compositions for oral administration include compressed tablets, pills, powders and granules.
  • one or more of the active compounds is, or are, admixed with at least one inert diluent such as starch, sucrose or lactose.
  • the compositions may also comprise, as is normal practice, additional substances other than inert diluents, e.g. lubricating agents, such as magnesium stearate.
  • Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art such as water and liquid paraffin. Besides inert diluents such compositions may comprise adjuvants, such as wetting and suspending agents, and sweetening, flavouring, perfuming and preserving agents.
  • the compositions according to the invention for oral administration also include capsules of absorbable material such as gelatin, containing one or more of the active substances with or without the addition of diluents or excipients.
  • Preparations according to the invention for parenteral administration include sterile aqueous, aqueous-organic, and organic solutions, suspensions and emulsions.
  • organic solvents or suspending media are propylene glycol, polyethylene glycol, vegetable oils such as olive oil and injectable organic esters such as ethyl oleate.
  • the compositions may also contain adjuvants such as stabilising, preserving, wetting, emulsifying and dispersing agents. They may be sterilised, for example, by filtration through a bacteria-retaining filter, by incorporation in the compositions of sterilising agents, by irradiation or by heating. They may also be manufactured in the form of sterile solid compositions, which can be dissolved in sterile water or some other sterile injectable medium immediately before use.
  • Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing the compound(s) of formula(e) I and/or (II).
  • the percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same time.
  • the dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient. In the adult, the doses are generally from 0.5 to 70, preferably 1 to 10, mg/kg body weight per day by oral administration.
  • No. 2 size gelatin capsules each containing:- (2 S ,4 R ,6 S )-6-[(4,5-diphenylimidazol-2-yl)thiomethyl]-4-hydroxy-2-methoxy-3,4,5,6-tetrahydro-2H-pyran 20 mg lactose 100 mg starch 60 mg dextrin 40 mg magnesium stearate 1 mg were prepared in accordance with the usual procedure.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention provides:
(2S,4R,6S)-6-[(4,5-diphenylimidazol-2-yl)thiomethyl]-4-­hydroxy-2-methoxy-3,4,5,6-tetrahydro-2H-pyran and (2R,4R,6S)-6-[(4,5-diphenylimidazol-2-yl)thiomethyl]-4-­hydroxy-2-methoxy-3,4,5,6-tetrahydro-2H-pyran or a mixture thereof; the compounds are anti-atherosclerotic agents.

Description

  • This invention relates to new, therapeutically useful imidazole derivatives, to a process for their production and to pharmaceutical compositions containing them.
  • The new imidazole derivatives of the present invention are the compounds of formulae (I) and (II) hereinafter depicted.
  • The compounds according to the invention are:-
    • (I) (2S,4R,6S)-6-[(4,5-diphenylimidazol-­2-yl)thiomethyl]-4-hydroxy-2-methoxy-3,4,5,6-­tetrahydro-2H-pyran; and
    • (II) (2R,4R,6S)-6-[(4,5-diphenylimidazol-­2-yl)thiomethyl]-4-hydroxy-2-methoxy-3,4,5,6-­tetrahydro-2H-pyran.
  • The invention also encompasses mixtures of compounds (I) and (II).
  • The compounds according to the invention are inhibitors of acyl coenzyme-A:cholesterol-O-acyl transferase (ACAT;EC 2.3.1.26). They are therefore of value as anti-atherosclerotic agents and have utility in the treatment of atherosclerosis, hyperlipidaemia, cholesterol ester storage disease and atheroma in vein grafts.
  • In in-vitro tests, using microsomes obtained from the livers of rats fed on a diet containing 0.5%w/w cholesterol and 0.25%w/w cholic acid, the compounds according to the invention were found to give IC₅₀ figures as shown in Table I, wherein IC₅₀ is the concentration required to produce a 50% inhibition in the activity of acyl coenzyme-A:cholesterol-O-acyl transferase. Table 1
    Compound IC₅₀(nM)
    (I) 50
    (II) 91
  • According to a feature of the invention, the compounds of formulae (I) and (II) are made by the desilylation of compounds of formula (III), in which R¹, R², and R³ , which can be identical or different, each represent a straight or branched-chain alkyl group containing 1 to 4 carbon atoms, or an optionally substituted phenyl group (the optional substituent being one which is inert to the reaction conditions and which does not cause any reaction other than the desilylation to occur). This is carried out by a conventional reagent such as an ammonium fluoride (e.g. tetrabutylammonium fluoride) in an anhydrous, inert solvent (e.g. an ether, such as tetrahydrofuran), preferably at room temperature. For example the group SiR¹R²R³ can be the t-butyldimethylsilyl group.
  • Compounds of formula (III) constitute a further feature of the invention.
  • Compounds of formula (III) are made by the reaction of the compounds of formula (IV), wherein R¹, R², and R³ are as hereinabove defined, with the compound of formula (V). This reaction is carried out, preferably under dry conditions, in the presence of a base, such as potassium carbonate, optionally under an inert atmosphere (e.g. argon), in an inert solvent, such as dimethylsulphoxide, optionally with heating (e.g. up to 60°C).
  • This reaction may result in epimerisation at the methoxy-bearing carbon atom and as a result the desilylation reaction which gives the compounds of formulae (I) and (II) may produce an anomeric mixture. Compounds (I) and (II) can be separated by conventional means, such as chromatography over silica gel using a suitable eluant.
  • The compounds of formula (IV) may be made by the method of T. Rosen et.al. [J.Org.Chem, (1984), 49, 3994].
  • Compounds of formulae (I) and (II) can be purified by the usual physical means, for example by crystallisation or chromatography.
  • The following Examples illustrate the preparation of the compounds according to the invention and the Reference Example illustrates the preparation of the intermediates of formula (III).
  • All N.M.R. spectra were recorded at 200MHz. Chemical shifts are expressed in ppm relative to tetramethylsilane. Abbreviations have the following significances:-
    s = singlet
    ss = singlets
    d = doublet
    t = triplet
    m = multiplet
    Figure imgb0001
    • EXAMPLE 1 Compounds (I) and (II)
  • A solution of a mixture of (2S,4R,6S)-4-­t-butyldimethylsilyloxy-6-[(4,5-diphenylimidazol-2-yl)­thiomethyl]-2-methoxy-3,4,5,6-tetrahydro-2H-pyran and (2R,4R,6S)-4-t-butyldimethylsilyloxy-6-[(4,5-­diphenylimidazol-2-yl)thiomethyl]-2-methoxy-3,4,5,6-­tetrahydro-2H-pyran (3.5g), in dry tetrahydrofuran (70ml), was treated with a solution of tetrabutylammonium fluoride in tetrahydrofuran, (1.0M;100ml) and the mixture was left to stand at room temperature for 18 hours. The solution was then poured into water, and was extracted with ethyl acetate. The combined extracts were washed with water, then dried over magnesium sulphate, and were concentrated at reduced pressure to give a gum (4.04g). This was chromatographed on silica gel, eluting with a mixture of ethyl acetate and hexane (3:1v/v), to give:- (2S,4R,6S)-6-[(4,5-diphenylimidazol-2-yl)thiomethyl]-­4-hydroxy-2-methoxy-3,4,5,6-tetrahydro-2H-pyran (1.74g), in the form of a white solid, m.p. 80-108°C
    [N.M.R. (CDCl₃):- 1.26 (1.5H, t), 1.65-2.02 (4H, m), 2.4 (1.5H, s), 3.06-3.6 (2H, m), 3.46 (3H, s), 4.06-4.2 (2H, m), 4.35-4.5 (1H, m), 4.9 (1H, d), 7.1-7.8 (10H, m), 10.46 (1H, s);
    Elemental analysis:- C, 65.3, H, 6.1, N, 6.7, S, 7.7%;
    Calculated for C₂₂,H₂₄N₂SO₃,0.5CH₃COOC₂H₅:- C, 65.43, H,6.41, N,6.36, S,7.28%]; and
    (2R,4R,6S)-6-[(4,5-diphenylimidazol-2-yl)thiomethyl]-­4-hydroxy-2-methoxy-3,4,5,6-tetrahydro-2H-pyran (0.27g), in the form of a white solid, m.p. 202-203°C
    [N.M.R. (CDCl₃):- 1.26 (0.75H, t), 1.5-1.75 (2H, m), 1.8-2.0 (2H, m), 2.4 (0.75H, s), 3.1-3.5 (2H, m), 3.38 (3H, s), 4.0-4.4 (3.5H, m), 4.81 (1H, dd), 7.0-7.8 (10H, m);
    Elemental analysis:-C, 65.6, H, 6.07,N, 6.79, S, 7.7%.
    Calculated for C₂₂H₂₄N₂SO₃,0.25CH₃COOC₂H₅:- C, 66.00, H, 6.26, N, 6.70, S, 7.66%].
    • REFERENCE EXAMPLE Compound (III)
  • A mixture of 4,5-diphenyl-2-mercaptoimidazole, (3.61g), (2S,4R,6S)-4-t-butyldimethylsilyloxy-6-­ iodomethyl-2-methoxy-3,4,5,6-tetrahydro-2H-pyran (3.7g), and anhydrous potassium carbonate (4.02g), was stirred and heated at 60° under argon in dry dimethyl­sulphoxide (60ml) for 4.5hours. The mixture was cooled and poured into water (400ml), and was extracted with ethyl acetate (4x100ml). The ethyl acetate extract was washed with water, brine, and was dried over magnesium sulphate. The extract was concentrated under reduced pressure to give an oil which was chromatographed on silica gel, eluting with a mixture of hexane and ethyl acetate (4:1v/v), to give a mixture of (2S,4R,6S)-­4-t-butyldimethylsilyloxy-6-(4,5-diphenylimidazol-2-­yl)thiomethyl]-2-methoxy-3,4,5,6-tetrahydro-2H-pyran and (2R,4R,6S)-4-t-butyldimethylsilyloxy-6-[(4,5-­diphenylimidazol-2-yl)thiomethyl]-2-methoxy-3,4,5,6-­tetrahydro-2H-pyran (3.58g) in the form of a gum.
    [N.M.R. (CDCl₃): 0.2,0.3 (6H, 2s), 0.9 (9H, ss) 1.5-1.9 (4H, m), 2.95-3.3 (2H, m), 3.1 (2.6H, s), 3.20 (0.4H, s), 4.42-4.6 (1H, m), 4.8-4.9 (1H, m), 7.1-7.7 (10H, m)].
  • The present invention also includes within its scope pharmaceutical formulations which comprise the compound(s) of formula(e) (I) and/or (II) in association with a pharmaceutically acceptable carrier or coating. In clinical practice the compounds of the present invention may be administered parenterally, rectally or orally.
  • Solid compositions for oral administration include compressed tablets, pills, powders and granules. In such solid compositions, one or more of the active compounds is, or are, admixed with at least one inert diluent such as starch, sucrose or lactose. The compositions may also comprise, as is normal practice, additional substances other than inert diluents, e.g. lubricating agents, such as magnesium stearate.
  • Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art such as water and liquid paraffin. Besides inert diluents such compositions may comprise adjuvants, such as wetting and suspending agents, and sweetening, flavouring, perfuming and preserving agents. The compositions according to the invention for oral administration also include capsules of absorbable material such as gelatin, containing one or more of the active substances with or without the addition of diluents or excipients.
  • Preparations according to the invention for parenteral administration include sterile aqueous, aqueous-organic, and organic solutions, suspensions and emulsions. Examples of organic solvents or suspending media are propylene glycol, polyethylene glycol, vegetable oils such as olive oil and injectable organic esters such as ethyl oleate. The compositions may also contain adjuvants such as stabilising, preserving, wetting, emulsifying and dispersing agents. They may be sterilised, for example, by filtration through a bacteria-retaining filter, by incorporation in the compositions of sterilising agents, by irradiation or by heating. They may also be manufactured in the form of sterile solid compositions, which can be dissolved in sterile water or some other sterile injectable medium immediately before use.
  • Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing the compound(s) of formula(e) I and/or (II).
  • The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same time. The dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient. In the adult, the doses are generally from 0.5 to 70, preferably 1 to 10, mg/kg body weight per day by oral administration.
  • The following Example illustrates pharmaceutical compositions according to the present invention.
    • COMPOSITION EXAMPLE 1
  • No. 2 size gelatin capsules each containing:-
    (2S,4R,6S)-6-[(4,5-diphenylimidazol-2-yl)thiomethyl]-4-hydroxy-2-methoxy-3,4,5,6-tetrahydro-2H-pyran 20 mg
    lactose 100 mg
    starch 60 mg
    dextrin 40 mg
    magnesium stearate 1 mg
    were prepared in accordance with the usual procedure.

Claims (5)

1. An imidazole derivative which is: (2S,4R,6S)-6-[(4,5-diphenylimidazol-2-yl)thiomethyl]-4-­hydroxy-2-methoxy-3,4,5,6-tetrahydro-2H-pyran or (2R,4R,6S)-6-[(4,5-diphenylimidazol-2-yl)thiomethyl]-4-­hydroxy-2-methoxy-3,4,5,6-tetrahydro-2H-pyran or a mixture thereof.
2. A process for the preparation of (2S,4R,6S)-6-[(4,5-diphenylimidazol-2-yl)thiomethyl]-4-­hydroxy-2-methoxy-3,4,5,6-tetrahydro-2H-pyran or (2R,4R,6S)-6-[(4,5-diphenylimidazol-2-yl)thiomethyl]-4-­hydroxy-2-methoxy-3,4,5,6-tetrahydro-2H-pyran, which process comprises the desilylation of a compound of the general formula:
Figure imgb0002
 in which R¹, R² and R³, which are identical or different, each represents a straight- or branched-chain alkyl group containing 1 to 4 carbon atoms or an optionally substituted phenyl group.
3. A pharmaceutical composition which comprises (2S,4R,6S)-6-[(4,5-diphenylimidazol-2-yl)thiomethyl]-4-­hydroxy-2-methoxy-3,4,5,6-tetrahydro-2H-pyran or (2R,4R,6S)-6-[(4,5-diphenylimidazol-2-yl)thiomethyl]-4-­hydroxy-2-methoxy-3,4,5,6-tetrahydro-2H-pyran or a mixture thereof, in association with a pharmaceutically acceptable carrier or coating.
4. (2S,4R,6S)-6-[(4,5-Diphenylimidazol-2-yl)thiomethyl]-­4-hydroxy-2-methoxy-3,4,5,6-tetrahydro-2H-pyran or (2R,4R,6S)-6-[(4,5-diphenylimidazol-2-yl)thiomethyl]-4-hydroxy-­2-methoxy-3,4,5,6-tetrahydro-2H-pyran, or a mixture thereof, for use in a method of treatment of the human or animal body.
5. A compound of the general formula:
Figure imgb0003
 wherein R¹, R² and R³, which are identical or different, each represents a straight- or branched-chain alkyl group containing 1 to 4 carbon atoms or an optionally substituted phenyl group.
EP90400918A 1989-04-05 1990-04-04 New imidazole derivatives, process for their production and pharmaceutical compositions containing them Withdrawn EP0391796A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8907656 1989-04-05
GB898907656A GB8907656D0 (en) 1989-04-05 1989-04-05 New compositions of matter

Publications (1)

Publication Number Publication Date
EP0391796A1 true EP0391796A1 (en) 1990-10-10

Family

ID=10654500

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90400918A Withdrawn EP0391796A1 (en) 1989-04-05 1990-04-04 New imidazole derivatives, process for their production and pharmaceutical compositions containing them

Country Status (5)

Country Link
US (1) US5006546A (en)
EP (1) EP0391796A1 (en)
JP (1) JPH03115280A (en)
CA (1) CA2013845A1 (en)
GB (1) GB8907656D0 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013876A1 (en) * 1990-03-16 1991-09-19 Rhone-Poulenc Rorer Limited Imidazoles

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2933739B2 (en) * 1990-04-09 1999-08-16 明治製菓株式会社 Thiazole or imidazole derivatives and anti-ulcer agents
US5252439A (en) * 1991-06-05 1993-10-12 Fuji Photo Film Co., Ltd. Method of replenishing developing solution with replenisher
ATE386716T1 (en) * 2000-12-26 2008-03-15 Pola Pharma Inc BIPHENYL DERIVATIVES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2635876A1 (en) * 1975-08-11 1977-03-03 Du Pont IMIDAZOLE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THEM
US4160666A (en) * 1977-05-25 1979-07-10 Eastman Kodak Company Polymeric chemical sensitizers for organic photoconductive compositions
EP0043788A1 (en) * 1980-07-03 1982-01-13 Schering Aktiengesellschaft Imidazole derivatives, process for their preparation and their pharmaceutical compositions
EP0252476A2 (en) * 1986-07-07 1988-01-13 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted) pyrazol-4-yl)-ethyl]- or ethenyl] tetrahydro-4-hydroxypyran-2-one-derivatives a process for their preparation and the use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714179A (en) * 1970-09-08 1973-01-30 Searle & Co 1-alkyl-2-furfurylthioimidazoles and congeners
GB2038825B (en) * 1978-12-16 1983-02-09 Wyeth John & Brother Ltd Heterocyclic compounds substituted by heterocyclyl-alkyl-thio groups
EP0055059B1 (en) * 1980-12-12 1985-03-27 Sankyo Company Limited Diazole and triazole derivatives, processes for their preparation and anti-microbial compositions containing them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2635876A1 (en) * 1975-08-11 1977-03-03 Du Pont IMIDAZOLE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THEM
US4160666A (en) * 1977-05-25 1979-07-10 Eastman Kodak Company Polymeric chemical sensitizers for organic photoconductive compositions
EP0043788A1 (en) * 1980-07-03 1982-01-13 Schering Aktiengesellschaft Imidazole derivatives, process for their preparation and their pharmaceutical compositions
EP0252476A2 (en) * 1986-07-07 1988-01-13 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted) pyrazol-4-yl)-ethyl]- or ethenyl] tetrahydro-4-hydroxypyran-2-one-derivatives a process for their preparation and the use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 102, no. 5, February 4, 1985 Columbus, Ohio, USA ABRAMOVA N. D. et al. "Alkylation of azole thio- nes." page 566, column 2, abstract -no. 45 836t *
CHEMICAL ABSTRACTS, vol. 103, no. 11, September 16, 1985 Columbus, Ohio, USA SHARPE, THOMAS R. et al. "Preparation, antiarthritic and analgesic activity of 4,5-diaryl-2-(substituted thio)-1H-imidazoles and their sulfoxides and sul- fones." page 603, column 2, abstract -no. 87 810f *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013876A1 (en) * 1990-03-16 1991-09-19 Rhone-Poulenc Rorer Limited Imidazoles

Also Published As

Publication number Publication date
US5006546A (en) 1991-04-09
CA2013845A1 (en) 1990-10-05
GB8907656D0 (en) 1989-05-17
JPH03115280A (en) 1991-05-16

Similar Documents

Publication Publication Date Title
EP0185359B1 (en) Oxetanone
US4004004A (en) Fusidic acid derivatives
EP0328111A2 (en) Cancer cell metastasis inhibitors
US4882316A (en) Pyrimidine derivatives
EP0180190B1 (en) 3,4-dihydrobenzopyran compounds and pharmaceutical composition containing the same
RU2264382C1 (en) New phenylethanolamine compounds as agonists of beta2-receptor and method for their preparing
EP0391796A1 (en) New imidazole derivatives, process for their production and pharmaceutical compositions containing them
US5089524A (en) Tetraenyl prostanoic acid derivatives as prodrugs for the treatment of peptic ulcer disease
US4341789A (en) Cycloaliphatic prostaglandin analogues
CS226034B2 (en) Method of preparing pyridine derivatives
EP0189272A2 (en) New furanone derivatives, processes for preparation thereof and use thereof
US4419356A (en) 2,3,6,7-Tetrahydrothiazolo[3,2-a]pyrimidine derivatives having anti-rheumatic properties and pharmaceutical compositions containing them
US4460595A (en) Using urazole analogs of prostaglandins for bronchodilation
US4136190A (en) 4,4-dimethyl-3,5-pyrrolidinediones
US5081245A (en) Carboxylic acid derivatives
HU201006B (en) Process for producing thioformamide derivatives and pharmaceutical compositions comprising same as active ingredient
EP0049144B1 (en) 5-fluoro uracil derivatives
US4185114A (en) Sulfur-containing N-benzylamino-acids and salts thereof
US4086343A (en) Acylated hydrazinopyridazine antihypertensives
US6071898A (en) Asiatic acid derivatives having modified A-ring
US5153220A (en) Tetraenyl prostanoic acid derivatives as prodrugs for the treatment of peptic ulcer disease
EP0046597B1 (en) 2,4-diazabicyclo(3.3.0)octane-3-one derivatives, their preparation and their pharmaceutical formulation
CH648483A5 (en) PHARMACEUTICAL COMPOSITION AGAINST RHUMATOID ARTHRITIS.
US4331673A (en) Pyridinium salts
US4177283A (en) Aromatic prostaglandin analogues

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19901221

17Q First examination report despatched

Effective date: 19921204

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930415